CD274 and neoplasm: There was no significant difference between treatment groups reported for median RFS in the all-randomly assigned patient population (HR 0.92, 95% CI 0.77-1.09, P= 0.269) or in patients with PD-L1 tumour expression <1% (HR 0.91, 95% CI 0.73-1.14), or in 2-year RFS rates according to disease stage (IIIB: HR 0.91, 95% CI 0.68-1.21; IIIC: HR 0.92, 95% CI 0.75-1.13; IIID: HR 1.61, 95% CI 0.70-3.67; IV: HR 0.88, 95% CI 0.58-1.32).20